Anna Kemp-Casey

Dr, BA PhD Murd.

Adjunct Research Fellow, Faculty of Health and Medical Sciences, Population and Public Health
Animal Techncian, Faculty of Health and Medical Sciences, UWA Centre for Medical Research

Emailanna.kemp@uwa.edu.au, anna.m.kemp@perkins.org.au

The University of Western Australia (M431), 35 Stirling Highway,
6009 Perth
Australia
The University of Western Australia (M519), 35 Stirling Highway,
6009 Perth
Australia

593 Citations
14 h-Index

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Dr Anna Kemp joined the Centre for Health Services at The University of Western Australia in 2007. Her primary research interest is the utilisation of publically subsidised prescription medicines in Australia and the impact of national health policy on their use, particularly among vulnerable population groups. Her other research activities are the analysis of whole-population prescription data, cost barriers to medicines use, methods for analysing policy impacts, pharmaco-vigilance and medicines safety, and health outcomes studies using linked health data. She has a growing reputation within Australian pharmacoepidemiology and pharmaceutical policy research and she is committed to contributing to community health and wellbeing through her research.

Roles and responsibilities

Former Member, Drug Utilisation Sub Committee of the Pharmaceutical Benefits Advisory Committee

Research Advisor, Population Health Research Network (PHRN) Proof of Concept (PoC) Reference Group

School of Population Health Consumer and Community Advisory Council

Funding overview

Roughead E, Ryan P, Graves S, Pratt N, Shakib S, Caughey G, Huang N, Kemp A. Centre of excellence in post-marketing surveillance of medicines and devices. NHMRC Centre for Research Excellence 2013-2017: $2.5 million.

Havard A, Jorm L, Preen D, Daube M, Kemp A, Einarsdottir K, Randall D. Pharmacotherapy for smoking cessation during pregnancy and the inter-pregnancy period: a population-based cohort study. NHMRC Project Grant 2012-2016: $620,950.

Preen D, Roughead L, Saunders C, Kemp A, Bulsara M, Holman CDJ. Endocrine therapies for early breast cancer: health outcomes and policy implications in Australian clinical practice. Cancer Australia 2011-2013: $466,498 (2011 $193,070; 2012 $136,714; 2013 $136,714).

Preen DB, Kemp A, Briffa T, Sanfilippo FM, Morlet N. Does treatment of age-related macular degeneration with intravitreal injection of vascular endothelial growth factor inhibitors increase arterial thromboembolic events? NSW Save Sight Institute, 2011: $53,764.

Kemp A, Ng J, 2009, '2010 - Does Treatment of Age-Related Macular Degeneration with Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors Increase Arterial Thromboembolic Events?', UWA Research Development Award Scheme, Funds Approved: $29,579.00.

Previous positions

Deputy Chair, Faculty of Medicine, Dentistry and Health Sciences Regional Human Research Ethics Committee.
Visiting Research Fellow, The Sax Institute, Sydney.
Visiting Research Fellow, Illawarra Health and Medical Research Institute, University of Wollongong.

Current projects

Endocrine therapy for early breast cancer: utilisation and outcomes in Australian practice.

Research

Impact of Pharmaceutical Benefits Scheme (PBS) policy changes on utilisation of prescription medicines and health services, utilisation of endocrine therapies for breast cancer, utilisation of opioids, analysis of linked health datasets

Research expertise keywords

Pharmacoepidemiology
Health record linkage
Cost barriers to medicine use
Health services research
Pharmaceutical Benefits Scheme (PBS) data
Medicare Benefits Schedule (MBS) data
Australian pharmaceutical policy
Hormone therapies for breast cancer

Fingerprint Dive into the research topics where Anna Kemp-Casey is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

19 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

593 Citations
14 h-Index
43 Article
4 Conference paper
3 Abstract/Meeting Abstract
1 Other chapter contribution
1 More
- 1 Letter

Frequent general practitioner visits are protective against statin discontinuation after a Pharmaceutical Benefits Scheme copayment increase

Seaman, K. L., Sanfilippo, F. M., Bulsara, M. K., Brett, T., Kemp-Casey, A., Roughead, E. E., Bulsara, C. & Preen, D. B., Jun 2020, In : Australian Health Review. 44, 3, p. 377-384 8 p.

Research output: Contribution to journal › Article

Predictors of ceasing or reducing statin medication following a large increase in the consumer copayment for medications: a retrospective observational study

Seamon, K., Sanfilippo, F., Bulsara, M., Roughead, L., Kemp-Casey, A., Bulsara, C., Watts, G. F. & Preen, D., 10 Mar 2020, In : Public Health Research & Practice. 30, 1

Research output: Contribution to journal › Article

Open Access

Use of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: A population-based cohort study

Tran, D. T., Preen, D. B., Einarsdottir, K., Kemp-Casey, A., Randall, D., Jorm, L. R., Choi, S. K. Y. & Havard, A., 5 Feb 2020, In : BMC Medicine. 18, 1, 15.

Research output: Contribution to journal › Article

Open Access

1 Citation (Scopus)

First trimester exposure to varenicline was not associated with increased risk of major birth defects: Findings from the smoking MUMS (Maternal Use of Medications and Safety) study

Tran, D. T., Preen, D. B., Einarsdottir, K., Kemp-Casey, A., Randall, D., Choi, S., Jorm, L. R. & Havard, A., Aug 2018, In : Pharmacoepidemiology and Drug Safety. 27, p. 352-352 1 p.

Research output: Contribution to journal › Abstract/Meeting Abstract